Cerebrolysin vs FGL

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Cerebrolysin is a brain-derived polypeptide preparation derived from porcine cortical tissue, composed of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic and neuroprotective effects. It is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity, and metabolic activity in damaged or degenerating brain tissue through multiple growth factor-like pathways. A Cochrane systematic review and multiple controlled clinical trials from Eastern European research groups have evaluated cerebrolysin for vascular dementia and stroke-related cognitive impairment, with mixed results that suggest potential benefit in specific post-stroke populations. Cerebrolysin is not FDA-approved; it is approved and widely used in Russia, Eastern Europe, and some Asian countries as a prescription neuroprotective treatment, and its evidence base reflects predominantly Eastern European clinical methodology with variable trial quality. Cerebrolysin price and access: Cerebrolysin is not available through standard US pharmacy channels; it is a prescription medication in the countries where it is approved (Russia, Eastern Europe, China, South Korea, and others) and is not FDA-approved. In markets where it is approved, cerebrolysin is administered intravenously in clinical settings — IV infusion courses of 10–20 sessions are the standard research and clinical protocol, with treatment costs varying significantly by country and clinic. Importation for personal use exists in a legal grey area in the United States; some wellness and peptide clinics may offer cerebrolysin as part of supervised protocols. Cancer-adjacent research: cerebrolysin's neurotrophic properties have drawn preclinical research interest in the context of chemotherapy-induced cognitive impairment (chemobrain), where neuroprotection during and after oncology treatment is a research priority. Autism spectrum disorder research: small controlled trials from Eastern European groups have evaluated cerebrolysin for speech and behavioral development in children with ASD, with mixed results; this remains an exploratory research area with no established clinical consensus. Stroke rehabilitation remains cerebrolysin's strongest evidence base, with multiple controlled trials evaluating cognitive and functional recovery in post-stroke patients.

Mimics NCAM-mediated signaling via FGFR (fibroblast growth factor receptor) activation. Stimulates downstream Erk1/2 and PLCγ pathways. Promotes long-term potentiation (LTP) and synaptogenesis.

FGL (EVYVVAENQQGKSKA) is a synthetic 15-amino-acid peptide derived from the fibronectin type III homology domain 2 of the neural cell adhesion molecule (NCAM), designed as a pharmacomimetic agonist of NCAM to activate FGFR-mediated neurotrophic signaling and mimic the synaptogenic and neuroprotective effects of NCAM receptor engagement in the central nervous system. FGL activates downstream FGFR signaling to promote synaptic plasticity, neuronal survival, and spatial learning in preclinical models; rodent studies have demonstrated cognitive-enhancing and anxiolytic effects in aged animals and in models of neurodegeneration, establishing a preclinical rationale for further investigation. No published human clinical trials, pharmacokinetic studies, or safety evaluations of FGL have been indexed in PubMed; the entirety of the evidence base consists of animal and in vitro studies, and no regulatory body has approved or evaluated FGL for any human indication. FGL has no FDA approval or regulatory approval in any jurisdiction; it is a research compound with a defined neurotrophic mechanism and an exclusively preclinical evidence base, and no clinical data exists to inform its pharmacokinetics, safety, or therapeutic utility in humans.